600196 复星医药
已收盘 04-24 15:00:00
资讯
新帖
简况
复星医药(02196):环丝氨酸胶囊上市注册申请获批准
智通财经 · 10分钟前
复星医药(02196):环丝氨酸胶囊上市注册申请获批准
复星医药(600196.SH):控股子公司自主研发的环丝氨酸胶囊获批上市
智通财经 · 17:02
复星医药(600196.SH):控股子公司自主研发的环丝氨酸胶囊获批上市
复星医药董秘回复: 张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官,复宏汉霖执行董事、董事会主席
证券之星 · 04-23 18:12
复星医药董秘回复: 张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官,复宏汉霖执行董事、董事会主席
创新高!复星医药(02196)入选全球药企管线规模前二十强
智通财经网 · 04-23 17:42
创新高!复星医药(02196)入选全球药企管线规模前二十强
大行花旗、瑞银、高盛等持续看好复星国际聚焦主业战略
中金在线 · 04-23 13:19
大行花旗、瑞银、高盛等持续看好复星国际聚焦主业战略
肝素概念盘中跳水,千红制药跌0.84%
自选股智能写手 · 04-23 10:41
肝素概念盘中跳水,千红制药跌0.84%
将“颜值”转化为“产值” 豫园股份与菏泽共建“中国牡丹”产业研究室
中国财富网 · 04-19
将“颜值”转化为“产值” 豫园股份与菏泽共建“中国牡丹”产业研究室
复星减持Ageas股份 进退有序 聚焦深挖矿
金融界 · 04-19
复星减持Ageas股份 进退有序 聚焦深挖矿
家庭医生概念盘中跳水,复星医药跌0.79%
自选股智能写手 · 04-19
家庭医生概念盘中跳水,复星医药跌0.79%
干细胞概念盘中拉升,开能健康涨3.26%
自选股智能写手 · 04-18
干细胞概念盘中拉升,开能健康涨3.26%
北向资金4月17日净买入复星医药24.57万股 连续3日增持
自选股智能写手 · 04-18
北向资金4月17日净买入复星医药24.57万股 连续3日增持
复星医药(02196.HK)子公司药物获批开展临床试验
阿斯达克财经 · 04-17
复星医药(02196.HK)子公司药物获批开展临床试验
复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理
阿斯达克财经 · 04-17
复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理
复星医药董秘回复: 1、复星健康前期在互联网和数字化方面的投入,大幅提升了公司的医疗数字化水平
证券之星 · 04-17
复星医药董秘回复: 1、复星健康前期在互联网和数字化方面的投入,大幅提升了公司的医疗数字化水平
复星医药:控股子公司获药物临床试验批准
每日经济新闻 · 04-17
复星医药:控股子公司获药物临床试验批准
复星医药(600196.SH):膦甲酸钠注射液获药品注册申请受理
格隆汇资讯 · 04-17
复星医药(600196.SH):膦甲酸钠注射液获药品注册申请受理
南向资金4月16日净买入复星医药149.70万股 连续5日增持
自选股智能写手 · 04-17
南向资金4月16日净买入复星医药149.70万股 连续5日增持
CAR-T疗法填补临床空白,复星凯特中国首款淋巴瘤按疗效价值支付计划关爱患者
新民晚报 · 04-16
CAR-T疗法填补临床空白,复星凯特中国首款淋巴瘤按疗效价值支付计划关爱患者
民营医院概念盘中跳水,复星医药跌1.50%
自选股智能写手 · 04-16
民营医院概念盘中跳水,复星医药跌1.50%
新冠药物概念盘中跳水,复星医药跌0.88%
自选股智能写手 · 04-16
新冠药物概念盘中跳水,复星医药跌0.88%
加载更多
公司概况
公司名称:
上海复星医药(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1998-08-07
主营业务:
上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7;根据IQVIA统计,2019年本集团生产的医院用处方药的销售收入位列全国第10。作为全球最大的抗疟药生产研发制造企业之一,本集团已成为全球基金、联合国儿童基金会、世界卫生组织及非洲各国药品采购中心的抗疟药供应商。本集团持续保持健康高质量发展。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。
发行价格:
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":22.73,"timestamp":1713942000000,"preClose":22.75,"halted":0,"volume":5584819,"delay":0,"floatShares":2118000000,"shares":2672000000,"eps":0.3899,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"04-24 15:00:00","open":22.76,"high":22.77,"low":22.46,"amount":126000000,"amplitude":0.0136,"askPrice":22.74,"askSize":134,"bidPrice":22.73,"bidSize":348,"shortable":0,"etf":0,"ttmEps":0.3899,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714008600000},"adr":0,"adjPreClose":22.75,"symbolType":"stock","openAndCloseTimeList":[[1713922200000,1713929400000],[1713934800000,1713942000000]],"highLimit":25.03,"lowLimit":20.48,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2672398711,"pbRate":1.33,"roa":"--","roe":"5.29%","epsLYR":0.89,"committee":-0.282196,"marketValue":60744000000,"floatMarketCap":48153000000,"peRate":58.296999,"changeRate":-0.0009,"turnoverRate":0.0026,"status":1},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2429143588","title":"复星医药(02196):环丝氨酸胶囊上市注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2429143588","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429143588?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:22","pubTimestamp":1713954176,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,上海复星医药(集团)股份有限公司控股子公司沈阳红旗制药有限公司自主研发的环丝氨酸胶囊用于对该药敏感的结核菌引起的且经一线抗结核药(如链霉素、异烟肼、利福平和乙胺丁醇)治疗效果不佳的活动性肺结核和肺外结核(包括肾结核)治疗的上市注册申请于近日获国家药品监督管理局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108733.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429828754","title":"复星医药(600196.SH):控股子公司自主研发的环丝氨酸胶囊获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2429828754","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429828754?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:02","pubTimestamp":1713949347,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)公告,公司控股子公司沈阳红旗制药有限公司自主研发的环丝氨酸胶囊(以下简称“该新药”)用于对该药敏感的结核菌引起的且经一线抗结核药(如链霉素、异烟肼、利福平和乙胺丁醇)治疗效果不佳的活动性肺结核和肺外结核(包括肾结核)治疗的上市注册申请于近日获国家药品监督管理局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108518.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429164192","title":"复星医药董秘回复: 张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官,复宏汉霖执行董事、董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164192","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429164192?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:12","pubTimestamp":1713867125,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药(600196)04月23日在投资者关系平台上答复投资者关心的问题。投资者:请问张文杰在公司主要负责哪方面工作?复星医药董秘:投资者您好,感谢您对公司的关注。张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官,复宏汉霖执行董事、董事会主席,以及合营公司复星凯特董事长。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231812078b4a279c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231812078b4a279c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429116122","title":"创新高!复星医药(02196)入选全球药企管线规模前二十强","url":"https://stock-news.laohu8.com/highlight/detail?id=2429116122","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429116122?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:42","pubTimestamp":1713865341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,近日,全球知名咨询机构Citeline发布《2024年医药研发年度回顾》白皮书,并评选出全球TOP 25管线规模的制药公司,复星医药连续第三年入选,位列第17位,较上年度跃升7个名次。白皮书显示,2023年,全球新药研发管线规模再创新高,中国正不断巩固其世界第二大新药研发的市场地位,中美药企的创新管线规模数量差距正在不断缩小。同时,复星医药持续推动管线内疫苗的研发和产业化落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107603.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429877130","title":"大行花旗、瑞银、高盛等持续看好复星国际聚焦主业战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2429877130","media":"中金在线","top":-1,"share":"https://www.laohu8.com/m/news/2429877130?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:19","pubTimestamp":1713849541,"startTime":"0","endTime":"0","summary":"近日,复星国际在2023年度业绩公布后,接连获投资大行唱好。瑞银于3月底发表的研报,也看好复星国际聚焦主业的战略,指出未来复星将继续坚定执行退出非核心资产策略,集中资源于可持续的、可预测的、稳定的核心业务,力图在这些领域实现更高效的资源配置和利润增长。瑞银预计,随着中国经济增长动能的恢复、复星“瘦身健体”策略的继续执行,以及未来对股东的分红持续增加,复星国际的估值将进一步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231320518b48ebd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231320518b48ebd1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429546135","title":"肝素概念盘中跳水,千红制药跌0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429546135","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429546135?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:41","pubTimestamp":1713840086,"startTime":"0","endTime":"0","summary":"04月23日,肝素概念盘中跳水,截至10点41分,肝素概念整体指数下跌1.03%,报676.940点。从个股上来看,该概念的成分股中,千红制药跌0.84%,红日药业、复星医药、力生制药跌幅居前。从资金上来看,截止发稿,肝素概念主力净流入为-2858.15万,其中复星医药受到资金热捧,主力净流入684.62万;拉长时间线来看,该板块近20日主力资金净流入-8.18亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423104127861e80ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423104127861e80ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428655653","title":"将“颜值”转化为“产值” 豫园股份与菏泽共建“中国牡丹”产业研究室","url":"https://stock-news.laohu8.com/highlight/detail?id=2428655653","media":"中国财富网","top":-1,"share":"https://www.laohu8.com/m/news/2428655653?lang=zh_cn&edition=full","pubTime":"2024-04-19 19:50","pubTimestamp":1713527453,"startTime":"0","endTime":"0","summary":"4月17日,豫园股份旗下复星津美化妆品与山东省菏泽市牡丹发展服务中心正式签订战略合作协议,启动共建“中国牡丹”产业研究实验室,助力菏泽产业提升自主科创研发能力,以新质生产力开辟国内化妆品产业与花卉产业高质量发展新路径。此番“中国牡丹”产业研究实验室的创建进一步推动了“美丽经济”与“花样经济”的共鸣。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191959278795a2c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191959278795a2c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428096688","title":"复星减持Ageas股份 进退有序 聚焦深挖矿","url":"https://stock-news.laohu8.com/highlight/detail?id=2428096688","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428096688?lang=zh_cn&edition=full","pubTime":"2024-04-19 14:14","pubTimestamp":1713507277,"startTime":"0","endTime":"0","summary":"近期,复星在 保险 业务领域的一系列动作引发市场广泛关注。复星出售Ageas股份,将获得约6.26亿至6.70亿欧元的交易对价,并预计实现未经审计税前利润约6,000万至6,500万欧元,这不仅有助于其精简和优化投资组合,还能提升其财务表现与核心业务竞争力。复星聚焦主业“深挖矿”的战略成果,在其核心子公司核心业务上得到最为充分的体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191419428b39790c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191419428b39790c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428577419","title":"家庭医生概念盘中跳水,复星医药跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428577419","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428577419?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:25","pubTimestamp":1713493551,"startTime":"0","endTime":"0","summary":"04月19日,家庭医生概念盘中跳水,截至10点25分,家庭医生概念整体指数下跌1.02%,报819.310点。从个股上来看,该概念的成分股中,复星医药跌0.79%,福瑞股份、中国平安、思创医惠跌幅居前。从资金上来看,截止发稿,家庭医生概念主力净流入为-3.63亿,其中中元股份受到资金热捧,主力净流入298.64万;拉长时间线来看,该板块近20日主力资金净流入-68.76亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910255187e81fef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910255187e81fef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428835885","title":"干细胞概念盘中拉升,开能健康涨3.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428835885","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428835885?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:51","pubTimestamp":1713405088,"startTime":"0","endTime":"0","summary":"04月18日,干细胞概念盘中拉升,截至09点51分,干细胞概念整体指数上涨0.52%,报723.850点。从个股上来看,该概念的成分股中,开能健康涨3.26%,九 芝 堂、苏常柴A、复星医药涨幅居前。从资金上来看,截止发稿,干细胞概念主力净流入为-2727.32万,其中复星医药受到资金热捧,主力净流入493.72万;拉长时间线来看,该板块近20日主力资金净流入-15.02亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809512887e8186c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809512887e8186c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428558583","title":"北向资金4月17日净买入复星医药24.57万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428558583","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428558583?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:30","pubTimestamp":1713403808,"startTime":"0","endTime":"0","summary":"4月17日, 北向资金增持复星医药24.57万股,连续3日增持。截止当日收盘,沪股通共持有复星医药4799.05万股,占流通股2.26%。沪股通增持金额前五个股分别为国电电力、大秦铁路、同仁堂、中国平安、赤峰黄金。复星医药近5个交易日下跌1.21%,沪股通累计增持33.59万股;近20个交易日下跌9.24%,沪股通累计增持47.02万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180930448b32443f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180930448b32443f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428397631","title":"复星医药(02196.HK)子公司药物获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2428397631","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428397631?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:49","pubTimestamp":1713347340,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布,其子公司上海复宏汉霖生物技术股份有限公司(02696.HK) 近日收到国家药品监督管理局批准其自主研发的 HLX53(即抗 TIGIT 的Fc融合蛋白)联合汉斯状®(即斯鲁利单抗注射液)和汉贝泰®(即贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌(HCC)开展临床试验。复宏汉霖拟于条件具备后,于内地开展相关治疗方案的II期临床试验。(vc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343032/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428397269","title":"复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428397269","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428397269?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:49","pubTimestamp":1713347340,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布,旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请,于近日获中国国家药品监督管理局受理。相关药物拟用于,获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎;以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月,集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343034/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428145392","title":"复星医药董秘回复: 1、复星健康前期在互联网和数字化方面的投入,大幅提升了公司的医疗数字化水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2428145392","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428145392?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:42","pubTimestamp":1713346921,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药04月17日在投资者关系平台上答复投资者关心的问题。投资者:1、复星健康这几年亏损严重是因互联网投入巨大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171742028b2e49db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171742028b2e49db&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428439149","title":"复星医药:控股子公司获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2428439149","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2428439149?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:55","pubTimestamp":1713344100,"startTime":"0","endTime":"0","summary":"复星医药(SH 600196,收盘价:22.78元)4月17日晚间发布公告称,上海复星医药(集团)股份有限公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司于近日收到国家药品监督管理局关于同意其自主研发的HLX53联合汉斯状®和汉贝泰®一线治疗局部晚期或转移性肝细胞癌(HCC)开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展该治疗方案的II期临床试验。2023年1至12月份,复星医药的营业收入构成为:药品制造与研发占比73.0%,医疗服务占比16.12%,医疗器械服务占比10.6%,其他产品占比0.28%。截至发稿,复星医药市值为609亿元。(文章来源:每日经济新闻)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716582487882776&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716582487882776&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428395454","title":"复星医药(600196.SH):膦甲酸钠注射液获药品注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428395454","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2428395454?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:36","pubTimestamp":1713342989,"startTime":"0","endTime":"0","summary":"格隆汇4月17日丨复星医药(600196.SH)公布,控股子公司桂林南药股份有限公司的膦甲酸钠注射液的药品注册申请于近日获国家药品监督管理局受理。该新药系化学药品,拟用于(1)获得性免疫缺陷综合征(AIDS)患者的巨细胞病毒性(CMV)视网膜炎;(2)免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性(HSV)的皮肤黏膜感染。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716363487880fd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716363487880fd0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428332668","title":"南向资金4月16日净买入复星医药149.70万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428332668","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428332668?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:31","pubTimestamp":1713317479,"startTime":"0","endTime":"0","summary":"4月16日, 南向资金增持复星医药149.70万股,连续5日增持。截止当日收盘,港股通共持有复星医药24978.96万股,占流通股45.24%。复星医药近5个交易日下跌8.23%,港股通累计增持470.85万股;近20个交易日下跌23.93%,港股通累计增持1245.30万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709493287869a1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709493287869a1b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427439598","title":"CAR-T疗法填补临床空白,复星凯特中国首款淋巴瘤按疗效价值支付计划关爱患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2427439598","media":"新民晚报","top":-1,"share":"https://www.laohu8.com/m/news/2427439598?lang=zh_cn&edition=full","pubTime":"2024-04-16 17:10","pubTimestamp":1713258629,"startTime":"0","endTime":"0","summary":"CAR-T细胞疗法具有个体化治疗的优势,能够根据患者的具体情况定制治疗方案,提供更精准、更有效的癌症治疗策略。另外,科室为接受CAR-T治疗患者免费提供CAR扩增和基因测序等检测,可帮助减轻患者的经济负担。2024年1月,复星凯特宣布推出“奕凯达中国首款淋巴瘤按疗效价值支付计划”,推动CAR-T细胞治疗产品惠及更多患者。据了解,奕凯达中国首款淋巴瘤按疗效价值支付计划将严格参照《2014版Lugano评估标准》评估CR结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041617151587838d14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041617151587838d14&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427869476","title":"民营医院概念盘中跳水,复星医药跌1.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427869476","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427869476?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:32","pubTimestamp":1713234761,"startTime":"0","endTime":"0","summary":"04月16日,民营医院概念盘中跳水,截至10点32分,民营医院概念整体指数下跌5.05%,报1421.700点。从个股上来看,该概念的成分股中,复星医药跌1.50%,京东方A、华邦健康、物产中大跌幅居前。从资金上来看,截止发稿,民营医院概念主力净流入为-2.43亿,其中人福医药受到资金热捧,主力净流入1313.92万;拉长时间线来看,该板块近20日主力资金净流入-43.75亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161032417a5302bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161032417a5302bd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427865552","title":"新冠药物概念盘中跳水,复星医药跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427865552","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427865552?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:06","pubTimestamp":1713233168,"startTime":"0","endTime":"0","summary":"04月16日,新冠药物概念盘中跳水,截至10点06分,新冠药物概念整体指数下跌4.69%,报458.010点。从个股上来看,该概念的成分股中,复星医药跌0.88%,东北制药、以岭药业、华邦健康跌幅居前。从资金上来看,截止发稿,新冠药物概念主力净流入为-1.62亿,其中中国医药受到资金热捧,主力净流入1850.82万;拉长时间线来看,该板块近20日主力资金净流入-43.94亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416100608861e60f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416100608861e60f9&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":0.0179},{"period":"1month","weight":-0.056},{"period":"3month","weight":0.0013},{"period":"6month","weight":-0.1651},{"period":"1year","weight":-0.2854},{"period":"ytd","weight":-0.0911}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267239万元","compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":-0.0085},{"period":"3month","weight":0.0713},{"period":"6month","weight":0.0113},{"period":"1year","weight":-0.0774},{"period":"ytd","weight":0.0158}],"survey":" 上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7;根据IQVIA统计,2019年本集团生产的医院用处方药的销售收入位列全国第10。作为全球最大的抗疟药生产研发制造企业之一,本集团已成为全球基金、联合国儿童基金会、世界卫生组织及非洲各国药品采购中心的抗疟药供应商。本集团持续保持健康高质量发展。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。","serverTime":1713954742079,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}